HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- None.
- None.
Insights
The recent findings on the MyoVista wavECG device present a significant advancement in the field of cardiac health, particularly in preoperative settings. The device's reported 100% sensitivity in detecting left ventricular diastolic dysfunction (LVDD) suggests a high potential for improving patient outcomes. LVDD is a critical factor in perioperative risk and its early detection is paramount in reducing complications during both cardiac and non-cardiac surgeries.
From a medical research perspective, the ability to exclude 25 out of 60 patients from unnecessary echocardiography based on MyoVista wavECG's results could lead to substantial cost savings and a reduction in the burden on healthcare systems. Furthermore, the integration of AI in ECG analysis is a promising trend, potentially leading to earlier and more accurate diagnoses of heart conditions.
However, the long-term implications of widespread adoption of such technology will require careful consideration of the accuracy of AI algorithms, the training of medical personnel and the standardization of protocols across different healthcare environments.
The integration of the MyoVista wavECG technology into preoperative screening protocols could represent a notable shift in healthcare resource allocation. By reducing the number of unnecessary echocardiograms, hospitals may experience a decrease in diagnostic-related expenditures. The reduction in referral rates to preoperative echocardiography, as demonstrated in the study, indicates potential for increased efficiency and cost-effectiveness in patient care.
Moreover, the potential for AI-ECG tools to be used in various care environments aligns with the growing trend towards personalized and precision medicine. The economic impact extends beyond immediate cost savings, as early detection of heart disease can lead to better management of the illness, potentially reducing expensive interventions later on.
It is important to analyze the cost-benefit ratio of implementing such technology, considering both the upfront costs of the devices and training, against the long-term savings from improved patient outcomes and reduced use of other diagnostic resources.
HeartSciences' announcement regarding the MyoVista wavECG could signal a significant market opportunity within the medical device sector. The focus on AI-powered diagnostic tools aligns with current industry trends emphasizing innovation and efficiency. The company's intention to make MyoVista commercially available in the short term suggests an aggressive go-to-market strategy that could disrupt the current standard of care for cardiac screening.
The medical device market is highly competitive and successful commercialization hinges on demonstrating clear advantages over existing solutions. The MyoVista wavECG's purported benefits must be communicated effectively to healthcare providers and insurers to gain market traction. Additionally, the development of hardware agnostic AI-ECG algorithms could broaden the appeal of HeartSciences' offerings and facilitate integration into existing healthcare infrastructures.
Investors and stakeholders should monitor the uptake of MyoVista wavECG post-commercialization, as well as any partnerships or collaborations that could accelerate its adoption in the market.
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended
Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the podium presentation of a study utilizing its MyoVista® wavECG device at the 18th World Congress of Anesthesiologists in Singapore.
Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries. In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled. For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
The author of the study stated in his presentation, “In our cohort of mixed surgical population, the MyoVista wavECG was useful as a screening tool with
“Once again, MyoVista wavECG has demonstrated significant potential value for screening in a large, at-risk patient population. The presentation of this study using the MyoVista to the World Congress of Anesthesiologists comes on the back of a recent publication assessing the use of MyoVista for identifying heart disease in diabetic patients1, which demonstrated MyoVista significantly outperformed existing standards of care,” said Andrew Simpson, Chief Executive Officer of HeartSciences. “AI-ECG and MyoVista provide the opportunity to screen for heart disease and transform cardiovascular medicine. We look forward to making the MyoVista device commercially available in the short term and also bringing to market a range of AI-ECG algorithms via a hardware agnostic platform. In combination, this will allow HeartSciences to provide AI-ECG solutions in any care environment worldwide.”
1 - Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus Cheng Hwee Soh1,2, Alex G. C. de Sá2,3,4,5, Elizabeth Potter1, Amera Halabi1, David B. Ascher2,3,4,5 and Thomas H. Marwick1,2,6*
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contacts:
HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com
Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com
FAQ
What was presented at the 18th World Congress of Anesthesiologists regarding MyoVista wavECG?
What was the sensitivity of MyoVista wavECG in detecting LVDD?
How does MyoVista wavECG impact referrals to preoperative echocardiography?
What is the potential of MyoVista wavECG in transforming cardiovascular medicine?
When will MyoVista wavECG be commercially available?
